| AASLD

Con: The Abstinence Period Should Be Determined on a Case‐by‐Case Basis

Read more about Con: The Abstinence Period Should Be Determined on a Case‐by‐Case Basis

Nikhilesh Mazumder, Justin Boike, Haripriya Maddur – 29 March 2019

Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study

Read more about Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study

Laure Elkrief, José Ferrusquia‐Acosta, Audrey Payancé, Lucile Moga, Luis Tellez, Michael Praktiknjo, Bogdan Procopet, Oana Farcau, Victor De Lédinghen, Rustam Yuldashev, Nicolas Tabchouri, Louise Barbier, Jérôme Dumortier, Benjamin Menahem, Marta Magaz, Virginia Hernández‐Gea, Agustin Albillos, Jonel Trebicka, Laurent Spahr, Andrea De Gottardi, Aurélie Plessier, Dominique Valla, Laura Rubbia‐Brandt, Christian Toso, Christophe Bureau, Juan‐Carlos Garcia‐Pagan, Pierre‐Emmanuel Rautou, for VALDIG, an EASL consortium – 29 March 2019 – In patients with idiopathic noncirrhotic portal hypertension

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps

Read more about Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps

Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri, DeLisa Fairweather, Sanda Win, Tin A. Than, Manal F. Abdelmalek, Ayako Suzuki – 29 March 2019 – Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age.

A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B

Read more about A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B

Jean‐François Rossignol, Christian Bréchot – 29 March 2019 – Chronic infection by the hepatitis B virus (HBV) has remained a major public health problem. To achieve an HBV cure, we will likely need to combine antivirals with different viral targets as well as immunotherapy. Here, we report data from a pilot proof‐of‐concept clinical trial of nitazoxanide in treating chronic hepatitis B. Conclusion: Nitazoxanide offers novel mechanisms of antiviral activity, and it would be interesting to evaluate the potential of combining nitazoxanide with oral nucleos(t)ide analogues.